Is KRYS a good stock to buy? We came across a bullish thesis on Krystal Biotech, Inc. on Investment Management Academy’s Substack. In this article, we will summarize the bulls’ thesis on KRYS. Krystal Biotech, Inc.’s share was trading at $310.30 as of May 28th. KRYS’s trailing and forward P/E were 41.55 and 45.45 respectively according to Yahoo Finance.
Likoper/Shutterstock.com
Krystal Biotech (KRYS) is a gene therapy company focused on rare diseases built around its proprietary HSV-1 vector platform, positioning it as a potential multi-product leader rather than a single-asset biotech. Its commercialized therapy VYJUVEK for DEB already generates high-margin, recurring revenue per patient in a highly underserved ultra-rare population, with significant room for expansion as global patient identification and international reimbursement broaden access.
Read More: 15 AI Stocks That Are Quietly Making Investors Rich
Read More: Undervalued AI Stock Poised For Massive Gains: 10000% Upside Potential
The investment thesis argues that the market is materially underappreciating both the continued growth runway of VYJUVEK and the optionality embedded in a seven-indication pipeline spanning dermatology, ophthalmology, respiratory, and oncology, where consensus assigns overly conservative success probabilities despite platform consistency. The core differentiator is the HSV-1 vector, which enables non-integrating gene delivery, repeat dosing, and high payload capacity, supporting durable commercial economics and replicable margins across future programs.
Key catalysts include European pricing resolution in Q3 2026, Italy’s clean launch in 2H 2026, KB801 and KB803 eye data by end-2026, KB407 cystic fibrosis Phase 3 enrollment in 1H 2026, and Q1 2026 earnings revealing accelerating international traction. The valuation framework highlights a base case upside of 52% to $407 per share driven by steady VYJUVEK scaling and initial pipeline validation, and a bull case of 96% upside to $523 per share driven by faster-than-expected pipeline commercialization and platform re-rating.
The bear case centers on clinical failure or stalled pipeline progression, limiting KRYS to a single-asset valuation. Overall, KRYS presents an asymmetric setup where rare disease monopolistic pricing power, underpenetrated patient pools, and expanding pipeline optionality collectively create a high-conviction long-term platform opportunity with meaningful upside if execution across its gene therapy pipeline continues to compound.
Previously, we covered a bullish thesis on CRISPR Therapeutics AG (CRSP) by MADD-Scientis in March 2025, highlighting its gene-editing platform, Casgevy commercialization, and pipeline optionality across oncology and in vivo programs driven by reimbursement traction and high margins. CRSP’s stock has appreciated by 37.61% since our coverage. Investment Management Academy shares a similar view but emphasizes Krystal Biotech’s HSV-1 platform, recurring rare disease revenues, and multi-indication expansion with a more concentrated VYJUVEK-led commercial base.
Krystal Biotech, Inc. is not on our list of the 40 Most Popular Stocks Among Hedge Funds. As per our database, 33 hedge fund portfolios held KRYS at the end of the first quarter which was 32 in the previous quarter. While we acknowledge the risk and potential of KRYS as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than KRYS and that has 10,000% upside potential, check out our report about this cheapest AI stock.
Disclosure: None.
